IMMUNOVANT

At Immunovant, we are applying a patient-focused approach to help advance treatments for these individuals... Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases... Immunovant's two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity.

Also known as: Immunovant Sciences GmbH, Immunovant, Inc.

Primary location: New York United States